Avenue Therapeutics Inc. (ATXI) Shares: Are They Risky Or Cheap?

0
6
TBLT
TBLT

Avenue Therapeutics Inc. (NASDAQ:ATXI) finished Thursday with an addition of $0.23 to close at $0.44, an upside of 105.90 percent. An average of 10,404,841 shares of common stock have been traded in the last five days. There was a gain of $0.1730 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 6,446,185 shares traded, while the 50-day average volume stands at 2,670,888.

ATXI stock has increased by 70.41% in the last month. The company shares reached their 1-month lowest point of $0.2013 on 09/13/22. With the stock rallying to its 52-week high on 03/01/22, shares of the company touched a low of $0.20 and a high of $1.85 in 52 weeks. It has reached a new high 2 times so far this year and lost -51.54% or -$0.4680 in price. In spite of this, the price is down -76.22% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Valuation Metrics

Avenue Therapeutics Inc. (ATXI) stock’s beta is 0.92. Other valuation ratios to consider include the price-to-book (PB) ratio at 14.67.

Financial Health

The quick ratio of Avenue Therapeutics Inc. for the three months ended September 29 was 2.50, and the current ratio was 2.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Avenue Therapeutics Inc.’s return on assets was -275.90%.

Earnings Surprise

The company posted a net income of -$0.6 million in the quarter, while revenues of -$2.86 million were shrunk -58.33%. The analyst consensus anticipated Avenue Therapeutics Inc.’s latest quarter earnings to come in at -$0.05 per share, but it turned out to be -$0.05, a 0.00% surprise. At the end of the quarter ending September 29, Avenue Therapeutics Inc.’s stock balance sheet showed total liabilities of 0.41 million. Shareholders own equity worth $22.14 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Avenue Therapeutics Inc. (ATXI) price momentum. RSI 9-day as of the close on 22 September was 72.61%, suggesting the stock is Overbought, with historical volatility in this time frame at 469.93%.

As of today, ATXI’s price is $0.2709 +64.79% or $0.1730 from its 5-day moving average. ATXI is currently trading +71.87% higher than its 20-day SMA and +19.02% higher than its 100-day SMA. However, the stock’s current price level is +62.30% above the SMA50 and -66.41% below the SMA200.

The stochastic %K and %D were 23.51% and 12.01%, respectively, and the average true range (ATR) was 0.0922. With the 14-day stochastic at 61.41% and the average true range at 0.0759, the RSI (14) stands at 68.34%. The stock has reached 0.0217 on the 9-day MACD Oscillator while the 14-day reading was at 0.0362.

Analyst Ratings

The consensus rating for Avenue Therapeutics Inc. (ATXI) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ATXI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.

What is ATXI’s price target for the next 12 months?

Analysts predict a range of price targets between $12.00 and $12.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Avenue Therapeutics Inc. (ATXI) stock is $12.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here